Pay in 4 interest-free payments of $5.45 Learn more
Ships within 48 hours · Estimated delivery Oct 6 - Oct 11
By Application: T2DM dominates, Obesity growing fastest Type 2 Diabetes Mellitus maintained the dominant application position in the GLP-1 Receptor Agonist Market in 2025, driven by the large established prescriber base, comprehensive insurance coverage for diabetes indications, and the longer clinical history of GLP-1 therapy in diabetes management that has built physician comfort and treatment guideline endorsement
In addition, TB-500 may help reduce chronic pain, improve hair growth, and support cardiac and neurological repair
A specialized peptide testing lab could theoretically analyze a sample, but the cost would far exceed simply replacing the medication
Available for purchase globally, including the US and EU
Meanwhile, Retatrutides Phase 2 data showed a 2.02% A1C reduction in the diabetic subgroup alongside 19.7% weight loss
